Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07242469 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableLead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLCTrial completed · Enrollment target: estimated 52 to confirmed 53 · Primary and study completion dates changed from estimate of Sep 3, 2026 to Sep 2, 2026 · 1 moreShow 4 more changesShow less
Trial completed
Enrollment target: estimated 52 to confirmed 53
Primary and study completion dates changed from estimate of Sep 3, 2026 to Sep 2, 2026
Eligibility criteria expanded, about 8 words
MinorEnrollment closed, study ongoingSite details revised at 5 of 5 sitesv6Show 1 more changeShow less
Site details revised at 5 of 5 sites
MinorPrimary and study completion dates: Aug 28, 2026 to Sep 3, 2026v5
MinorStudy sites: 4 to 5v4
MinorSite details revised at 2 of 4 sitesv3
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 4 · Start date changed from estimate of Dec 18, 2025 to Dec 22, 2025v2Show 2 more changesShow less
Study sites: 0 to 4
Start date changed from estimate of Dec 18, 2025 to Dec 22, 2025
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.